

October 13 , 2018

Re: Submission of revised manuscript "POTASSIUM-COMPETITIVE ACID BLOCKERS - ARE THEY THE NEXT GENERATION OF PPI'S", Manuscript ID: 41814

The Editors

World Journal of Gastrointestinal Pharmacology and Therapeutics

Baishideng Publishing Group Inc.

Dear Editors and reviewers:

Thank you for the opportunity to review the manuscript, "POTASSIUM-COMPETITIVE ACID BLOCKERS - ARE THEY THE NEXT GENERATION OF PPI'S", Manuscript ID: 41814. We appreciate the careful review and suggestions. We believe that the article is markedly improved after making the suggested changes and edits. We agree to the changes requested and have added few additional changes.

Following this letter is the reply to the reviewer's comments point-by-point, and any additional changes we have made. The revision has been developed in consultation with all coauthors, and each author has given approval to the final form of this revision.

Thank you for your consideration.

Sincerely,

Prashanth Rawla, MD

REVIEWER 1 EVALUATION

This is a very nice concise review of a new class of compounds for acid peptic disorders that is well written and easily understood.

- Thank you.

Other than a few grammatical and spelling corrections, not major revision are needed.

- Thank you

Vonoprazan is misspelled on pages 3 and 5.

- Thank you for pointing out the mistakes. These have been corrected in pages 3 and 5.

ON page 4 in the second sentence under Mechanism of Action, the verb "was" needs to be added (it was exposed to vesicles) and the word "rather" needs to be added (rather than the ion-leaky ones).

- Thank you for the suggestions. Sentence has been corrected as per author instructions.

The last line on page 5 should say "slightly lower."

- Thank you for the suggestions. Sentence has been corrected as per author instructions.

On page 9 under Approval Status, it should say Vonoprazan "was" approved instead of "is approved."

- Thank you for the suggestions. Sentence has been corrected as per author instructions.

Similarly on the last page, "it was found that the drug was well tolerated," rather than "were found."

- Thank you for the suggestions. Sentence has been corrected as per author instructions.

All of the references need to be made to conform to the journal standards including DOI and PMID information (see instructions for authors).

- Thank you for the suggestions. References have been corrected to confirm to the journal standards including DOI and PMID information.

REVIEWER 2 EVALUATION (FROM THE WORD DOCUMENT)

1. Page 4 1st paragraph - it has been approved in Korea for esophagitis

(http://www.raqualia.com/rq-cms/wp-content/uploads/2018/07/300706_RaQualia-Announces-Receipt-of-Milestone-Payment-from-CJ-HealthCare.pdf)

- Thank you for the suggestion. In page 4 1st paragraph have made appropriate changes and updated the information on approval of tegoprazan

2. In page 4, 2nd paragraph change pKA to pKa

- Thank you for the suggestion. Changed to pKa.

3. Page 5 and page 11 Vonoprazan misspelled

- Thank you for the feedback, Spellings have been corrected.

4. Page 5 paragraph 2 last sentence – does not make sense as TAK438 is vonoprazan, delete it.

- Thank you for the feedback. Deleted the last sentence.

5. Page 6 para 3 “This should be typo (200 mg), since the standard dosage of Clarithromycin in Japan is 200 mg, rather than 2000 mg.”

- Thank you for the suggestion. Changed to dosage to 200mg.

6. Page 8 last para change tegaprazan to tegoprazan.

- Thank you for the feedback. Changed the spelling as suggested.

7. Page 9 2nd para – “The study has completed and also the indication has been approved in Japan[14].”

- Thank you for the suggestion. Deleted the line as suggested.

8. Page 10 “Irreversible (PPIs are irreversible inhibitor of proton pump)’

- Thank you for the feedback. Change it to irreversible inhibitors.

Correspondence concerning this paper should be addressed to:

Prashanth Rawla

E-mail: rawlap@gmail.com

Sincerely,

Prashanth Rawla